Could less be more? new trial shortens leukemia drug course for seniors

NCT ID NCT07437950

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. About 126 participants will be randomly assigned to one of two treatment schedules. The goal is to see if the shorter treatment can achieve the same deep remission with fewer side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

San Juan City Hospital
RECRUITING

San Juan, 00936, Puerto Rico
Trinity Health IHA Medical Group Hematology Oncology - Brighton
RECRUITING

Brighton, Michigan, 48114, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
RECRUITING

Canton, Michigan, 48188, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
RECRUITING

Chelsea, Michigan, 48118, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
RECRUITING

Ypsilanti, Michigan, 48197, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
RECRUITING

Pontiac, Michigan, 48341, United States
Trinity Health Saint Mary Mercy Livonia Hospital
RECRUITING

Livonia, Michigan, 48154, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.